John L. Lamattina's most recent trade in Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B was a trade of 2,161 Common Stock done at an average price of $200.8 . Disclosure was reported to the exchange on March 6, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Sale of securities on an exchange or to another person at price $ 200.76 per share. | 06 Mar 2026 | 2,161 | 30,724 (0%) | 0% | 200.8 | 433,842 | Common Stock |
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 114.15 per share. | 06 Mar 2026 | 2,161 | 32,885 (0%) | 0% | 114.1 | 246,678 | Common Stock |
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2026 | 2,161 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.13 per share. | 07 Nov 2025 | 2,145 | 32,869 (0%) | 0% | 66.1 | 141,849 | Common Stock |
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2025 | 2,145 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Sale of securities on an exchange or to another person at price $ 205.45 per share. | 07 Nov 2025 | 2,145 | 30,724 (0%) | 0% | 205.4 | 440,690 | Common Stock |
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2025 | 2,034 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Sale of securities on an exchange or to another person at price $ 205.45 per share. | 07 Nov 2025 | 2,034 | 30,724 (0%) | 0% | 205.4 | 417,885 | Common Stock |
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 69.51 per share. | 07 Nov 2025 | 2,034 | 32,758 (0%) | 0% | 69.5 | 141,383 | Common Stock |
| PureTech Health Plc ADR | John L. LaMattina | Non-Executive Director | Purchase of securities on an exchange or from another person at price $ 1.25 per share. | 23 Sep 2025 | 59,100 | 1,602,594 (0%) | 0% | 1.3 | 73,875 | Ords 0.01p |
| PureTech Health Plc ADR | John L. LaMattina | Non-Executive Director | 01 Jul 2025 | 59,202 | 1,543,494 (0%) | 0% | 0 | Ords 0.01p | ||
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 5,783 | 5,783 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 1,209 | 30,724 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.30 per share. | 27 Nov 2024 | 2,406 | 31,921 (0%) | 0% | 52.3 | 125,834 | Common Stock |
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Nov 2024 | 2,406 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Sale of securities on an exchange or to another person at price $ 123.65 per share. | 27 Nov 2024 | 2,406 | 29,515 (0%) | 0% | 123.7 | 297,502 | Common Stock |
| PureTech Health Plc ADR | John L. LaMattina | Non-Executive Director | 29 Oct 2024 | 52,640 | 1,484,292 (0%) | 0% | 0 | Ords 0.01p | ||
| PureTech Health Plc ADR | John L. LaMattina | Non-Executive Director | 26 Jun 2024 | 17,122 | 1,431,652 (0%) | 0% | 0 | Ords 0.01p | ||
| PureTech Health Plc ADR | John L. LaMattina | Non-Executive Director | Sale of securities on an exchange or to another person at price $ 2.50 per share. | 24 Jun 2024 | 54,882 | 1,359,648 (0%) | 0% | 2.5 | 137,205 | Ords 0.01p |
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 5,444 | 5,444 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 1,252 | 29,515 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 5,461 | 5,461 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 1,142 | 28,263 (0%) | 0% | 0 | Common Stock | |
| Immunome Inc | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 6,500 | 6,500 | - | - | Stock Option (Right to Buy) | |
| Immunome Inc | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 4.00 per share. | 15 Jan 2023 | 15,125 | 66,953 | - | 4 | 60,500 | Common Stock |
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2022 | 4,484 | 4,484 | - | - | Non-Qualified Stock Option (right to buy) | |
| Immunome Inc | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 6,500 | 6,500 | - | - | Stock Option (Right to Buy) | |
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 4,340 | 4,340 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 1,004 | 26,402 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Sale of securities on an exchange or to another person at price $ 161.86 per share. | 16 Nov 2021 | 4,835 | 25,398 (0%) | 0% | 161.9 | 782,579 | Common Stock |
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.30 per share. | 16 Nov 2021 | 4,835 | 30,233 (0%) | 0% | 32.3 | 156,171 | Common Stock |
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2021 | 4,835 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 3,269 | 3,269 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 630 | 25,398 (0%) | 0% | 0 | Common Stock | |
| Immunome Inc | John L. LaMattina | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 3,750 | 3,750 | - | - | Stock Option (Right to Buy) | |
| Immunome Inc | John L. LaMattina | Director | Purchase of securities on an exchange or from another person at price $ 18.58 per share. | 24 May 2021 | 5,102 | 51,828 | - | 18.6 | 94,795 | Common Stock |
| Immunome Inc | John L. LaMattina | Director | Purchase of securities on an exchange or from another person at price $ 18.44 per share. | 24 May 2021 | 338 | 46,726 | - | 18.4 | 6,233 | Common Stock |